Top U.S. Healthcare Stocks to Watch, According to Mizuho By Investing.com
Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
How this was made
The 30-second read
Why it matters
The article’s actionable elements are the specific upcoming clinical data windows and one regulatory PDUFA date, but it does not present new primary results or filings.
Market read
Useful for event-calendar building (Phase 3 and PDUFA timing), but it is not a new fundamental disclosure beyond analyst framing and stated milestones.
What to watch
Execution risk remains high for Phase 3 and regulatory timelines; also, discounting to competitors and guidance assumptions may not hold if endpoints or enrollment timelines slip.
Background
Mizuho compiled a multi-name US healthcare watchlist spanning ophthalmology, vaccines, oncology, dermatology, imaging, and inpatient rehab.
Ticker impact
Mizuho rates EyePoint Outperform and flags Phase 3 LUGANO Duravyu data expected in August 2026.
Moderate upside bias into August 2026 catalyst; near-term trading likely sentiment-driven.
The article provides a specific upcoming clinical data window and a fresh price target, but it is still an analyst note rather than new trial results.
Mizuho assigns Outperform to Vaxcyte, citing clean Phase 2 VAX-31 data and Phase 3 OPUS-1 timing in Q4 2026.
Potential positive drift as Q4 2026 OPUS-1 approaches; limited immediate fundamental change today.
The text adds concrete trial milestones and a PT, but does not disclose new Phase 3 outcomes.
Mizuho rates Erasca Outperform, highlighting ERAS-0015 62% response rate and expected ERAS-4001 Phase 1/1b data in H2 2026.
Likely positive sentiment into H2 2026; magnitude uncertain without new data release.
It includes a specific response-rate figure and future data timing, but remains within an analyst framing.
Mizuho reiterates upside for Arcutis, citing 2026 Zoryve sales guidance range and potential early-2027 FDA approval for under-2 atopic dermatitis.
Positive bias into early-2027 FDA decision window; near-term impact likely limited absent new regulatory updates.
The article provides guidance and an approval expectation, but it is not a new FDA action or filing.
Mizuho highlights Lantheus Pylarify PSMA PET growth expectations and a mid-August 2026 PDUFA date for MK-6240 in Alzheimer’s.
Increased volatility and upside skew into mid-August 2026; direction depends on FDA outcome.
A specific regulatory milestone date is provided, which is typically actionable for event-driven positioning.
Mizuho points to Encompass Health occupancy rising to 78.7% in Q1 2026 and plans bed additions through 2026-2027.
Mild-to-moderate positive bias as investors track occupancy and bed growth execution.
The article includes concrete occupancy and expansion details, but it is still an analyst watchlist rather than a new company filing.
Mizuho cites Solventum divestiture proceeds for accelerated debt paydown and notes recent beat-and-raise results despite YTD underperformance.
Supportive for credit and equity sentiment; near-term trading depends on how quickly debt paydown and efficiencies translate.
The article provides a specific corporate action (divestiture) and operational framing, but lacks deal terms or new financial statements.
Market effects
Reinforces a healthcare theme of event-driven catalysts across biotech, devices, imaging, and rehab services.
Primarily US healthcare sentiment; no direct cross-region catalyst described.
Limited, as the catalysts and companies are US-focused with no explicit global policy or supply-chain shock.
Counterpoint
These are analyst watchlist items with price targets; without new trial readouts or regulatory actions, near-term price moves may fade after initial positioning.
Key entities
- public_companyEyePoint, Inc.
Duravyu Phase 3 LUGANO data expected in August 2026 per Mizuho.
- public_companyVaxcyte
VAX-31 Phase 3 OPUS-1 non-inferiority data expected in Q4 2026 per Mizuho.
- public_companyErasca
ERAS-4001 Phase 1/1b monotherapy data expected in H2 2026 per Mizuho.
- public_companyArcutis Biotherapeutics
Potential early-2027 FDA approval for Zoryve Cream 0.05% in under-2 atopic dermatitis per Mizuho.
- public_companyLantheus Holdings
MK-6240 Alzheimer’s PDUFA slated for mid-August 2026 per Mizuho.
